Firmonertinib in advanced non-small cell lung cancer with epidermal growth factor receptor P-loop and αC-helix compressing mutations.

Firmonertinib achieves objective response rates of 43% and 68% in first-line treatment of EGFR PACC-mutant NSCLC, with median progression-free survival up to 16 months.

• Why it matters: EGFR PACC mutations are a distinct subgroup in NSCLC with limited treatment options, highlighting the need for targeted therapies that can effectively address this mutation class.
• What they did: The phase 1b FURTHER study evaluated 47 patients with metastatic EGFR PACC-mutant NSCLC receiving either 160 mg or 240 mg of firmonertinib, assessing objective response rates, progression-free survival, and safety.
• The result: Results indicate that firmonertinib has promising efficacy, including intracranial activity, and support further investigation of its use as a first-line treatment for this mutation subgroup.